CN 1
Alternative Names: CN-1Latest Information Update: 28 Aug 2023
At a glance
- Originator Curon Biopharmaceutical (Australia) Co Pty Ltd
- Class Antineoplastics; Immunotherapies
- Mechanism of Action CD4-positive T-lymphocyte stimulants; CD8 positive T lymphocyte stimulants; Cytokine stimulants; Regulatory T-lymphocyte modulators; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Lymphoma
- No development reported B-cell lymphoma; Solid tumours
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for phase-I development in B-cell lymphoma(Late-stage disease, Second-line therapy or greater) in Austria (IV, Infusion)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in Austria (IV, Infusion)
- 20 Oct 2022 Curon Biopharmaceutical (Australia) Co Pty Ltd terminates a phase I/II trial in Lymphoma (Combination therapy, Second-line therapy or greater) in Australia (PO) as the sponsor decided that there was no benefit in the drug treatment and due to company change in landscape in the new year (NCT04880564)